Alert detail
FDA Approval: HOVILPR (PRITELIVIR) — Type 1 - New Molecular Entity
Policy ID: FDA-NDA221154Specialty: Infectious DiseaseAdded: 10/17/2026Effective: October 9, 2026federal register
What changed
Oral pritelivir routes to Part D; no J-code expected.
Who’s affected: Infectious Disease billing teams · Effective: October 9, 2026
Primary source: View the official CMS/MAC document ↗
Get the action steps and full analysis
The full analysis, the revision comparison and the as-of-date version of this policy are what a partner packet carries. The source document above is free and always will be.